In a significant move that marks the largest biotech acquisition since 2023, Johnson & Johnson has announced its agreement to purchase neuroscience drugmaker Intra-Cellular Therapies for £14.6 billion. The New
Pharmaceutical11- Page
169Articles
In a devastating blow to investor confidence, Moderna’s shares experienced a dramatic decline of up to 22 per cent on Monday following disappointing sales forecasts from the US biotech giant.
Liverpool’s burgeoning life sciences sector is positioning itself as one of Europe’s premier biotech clusters, with projections indicating up to £800 million in investment over the next decade. The region’s
The struggling consumer healthcare company Alliance Pharma appears poised to exit London’s junior stock exchange following a £350 million takeover bid from activist investor Dbay Advisors. The Isle of Man-based
A groundbreaking series A funding round has positioned London-based Verdiva Bio at the forefront of the obesity treatment sector, securing an impressive $411 million investment. This remarkable achievement stands as
A landmark research initiative analysing blood proteins could catalyse significant advancements in disease treatment and prevention, presenting substantial opportunities for healthcare sector investors. The extensive UK-based study, backed by 14
British pharmaceutical giant GSK is in advanced negotiations to acquire IDRx, a Massachusetts-based biotechnology company, in a deal valued at approximately $1 billion. The announcement is expected to coincide with
Share prices of leading vaccine developers experienced significant gains on Tuesday following the announcement of America’s first human death from the H5 strain of bird flu. The market response saw
Novo Nordisk, the Danish pharmaceutical powerhouse, has invested hundreds of thousands of pounds in sponsorship deals with major UK pharmacy chains, including Boots and Lloyds, to enhance sales of its